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Introduction
Colorectal cancer (CRC) is one of the most frequent 
cancer types worldwide, with more than 70,000 new 
affected per year in the United States (Fransen et al., 
2004, Jemal et al., 2011). CRC progresses through a 
multi-step carcinogenic process with a gathering of 
epigenetic and genetic alterations, including KRAS 
and BRAF mutation (Imamura et al., 2012). The KRAS 
proto-oncogene encodes a GTPase which trigger signal 
transduction cascade of Influence of epidermal growth 
factor receptor/mitogen-activated protein kinases (EGFR/
MAPK pathway), resulting in recruits and activates BRAF 
(Campbell et al., 1998, Fransen et al., 2004, Guedes et 
al., 2013). BRAF, another factor of the EGFR/MAPK 
signaling pathway, produces a serine-threonine protein 
kinase that is a downstream molecule of actuated KRAS 
(Chen et al., 2014). BRAF mutant induces a signaling 
cascade involving factors in the MAPKs, resulting in cell 
propagation (Allegra et al., 2009, Guedes et al., 2013). 
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Abstract
 Background: The investigation of mutation patterns in oncogenes potentially can make available a reliable 
mechanism for management and treatment decisions for patients with colorectal cancer (CRC). This study 
concerns the rate of KRAS and BRAF genes mutations in Iranian metastatic colorectal cancer (mCRC) patients, 
as well as associations of genotypes with clinicopathological features. Materials and Methods: A total of 1,000 
mCRC specimens collected from 2008 to 2012 that referred to the Mehr Hospital and Partolab center, Tehran, 
Iran enrolled in this cross sectional study. Using HRM, Dxs Therascreen and Pyrosequencing methods, we 
analyzed the mutational status of KRAS and BRAF genes in these. Results: KRAS mutations were present in 
33.6% cases (n=336). Of KRAS mutation positive cases, 85.1% were in codon 12 and 14.9% were in codon 13. 
The most frequent mutation at KRAS codon 12 was Gly12Asp; BRAF mutations were not found in any mCRC 
patients (n=242). In addition, we observed a strong correlation of KRAS mutations with some clinicopathological 
characteristics. Conclusions: KRAS mutations are frequent in mCRCs while presence of BRAF mutations in 
these patients is rare. Moreover, associations of KRAS genotypes with non-mucinous adenocarcinoma and depth 
of invasion (pT3) were remarkable. 
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It has been demonstrated that mutation of KRAS and 
BRAF genes frequently observed in the early stages of 
CRC (Roth et al., 2010). Approximately 30% to 40% of 
CRC tissues harbor a mutated KRAS gene (Andreyev 
et al., 1998; Andreyev et al., 2001), and 90% of those 
mutations found in exon 2 of the KRAS gene (at codons 
12/13) (Janakiraman et al., 2010, De Roock et al., 2011). 
This mutant gene create a constitutively active ras factor 
that leads to EGFR-independent activation of the MAPK 
signaling pathway (Bos et al., 1987; Bamford et al., 
2004) and subsequent induces cell growth and resistance 
to apoptosis (Rajagopalan et al., 2002; Benvenuti et al., 
2007; Schubbert et al., 2007). Recent studies have shown 
that Almost 15% of CRC harbor the BRAF mutation 
(Deng et al., 2004; Roth et al., 2010) and approximately 
all BRAF-mutated CRC are existing within the KRAS 
wild-type cancers (Imamura et al., 2012). Mutations of 
the KRAS gene have been broadly studied as prognostic 
biomarkers for CRC (Hsieh et al., 2012). On the other 
hand the BRAF mutation has been correlated with lesser 
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prognosis in several studies (French et al., 2008; Farina-
Sarasqueta et al., 2010; Roth et al., 2010). However, 
mutation analysis of KRAS and BRAF genes, as members 
of EGFR/MAPK pathway, before the administration 
of anti-EGFR-targeted therapies for patients with CRC 
has become important (Rizzo et al., 2010). In CRCs, 
population-based investigations have proposed that the 
mutations might be correlated with some tumor features 
(Hsieh et al., 2012). However, the mutation rate and 
clinicopathological characteristics of KRAS/BRAF genes 
in Iranian CRC patients stay has been unclear. The aim 
of our study was to investigate the mutational activation 
of two members of the MAPK pathway, the KRAS gene 
in 1000 mCRC and BRAF gene in 242 mCRC tissue 
at stage IV in Iranian population by using HRM and 
Pyrosequencing techniques.
Materials and Methods
Study population
The biopsy specimens were obtained from 1000 
Iranian mCRC patients including 427 (42.7%) female 
(median age 55 yrs.) and 573 (57.3%) male (median age 
57 yrs.); their pathological data are listed in Table 1. These 
patients between 2008 and 2012 were referred to the Mehr 
Hospital and molecular diagnostic laboratory of Partolab, 
the main referral center for cancerous patients in Iran that 
located in Tehran, Iran. Written informed consent was 
obtained from all patients before testing. The study was 
approved by the ethical committee of Iran University of 
Medical sciences, Tehran, Iran.
Hematoxylin and Eosin (H&E)-stained slides from all 
CRC cases were reviewed by a sophisticated pathologist 
and at least 50% neoplastic tissues selected for mutation 
analysis. Unstained slides were immersed in xylene for 
5 minutes and twice in ethanol 100% for 5 minutes. 
Tumor areas were then delimited, by comparison with 
correspondent H&E stained slides, and macro dissected.
DNA extraction
Genomic DNA was extracted from dissected tissue 
using the methods described by the QIAamp® DNA FFPE 
Tissue Kit (QIAGEN, Hilden, Germany). Concentration 
(ng/ul) and purity (OD 260/280nm) of DNA was quantified 
by spectrophotometry with NanoDrop ND-1000® (Thermo 
Fisher Scientific Inc., Waltham, MA, USA). Extracted 
DNA was stored at - 20oC before use. 
High resolution melting (HRM)
To distinguish KRAS and or BRAF mutant from 
wild-type specimens, High resolution melting (HRM) 
was performed as a screening method. PCR amplification 
and HRM were performed on a LightCycler® 480 II Real-
Time System (Roche Diagnostics, Basel, Switzerland). 
Analysis provided with the software LightCycler® 480 
Gene Scanning Software Version 1.5 (Roche diagnostics) 
(Figure1). PCR reaction mixtures with a final volume of 10 
μl contained: The 0.5 µM forward primer, 0.5 µM reverse 
primer, 0.5 µM unlabelled probe with a 3’-conjugated C3 
spacer, 0.01 µg genomic DNA in 1× LightScanner Master 
mix (Idaho Technologies, Salt Lake City, UT, USA). Assay 
for KRAS performed by following program: one cycle 
of initial denaturation at 95oC 2 min; 50 cycles of 30 s 
95oC (denaturation); 30 s 64oC (annealing); 30 s 72oC 
(extension); and one cycle of 60 s 72oC, 20 s 95oC, 20 s 
55oC; final melting in two steps follows: Melt 1 (55-78oC 
at 0.06oC/s) followed by Melt 2 (78- 95oC, 0.06oC/s) 
and recorded of the fluorescent level. The termocycler 
conditions for BRAF HRM assay were: 95°C 10 min; 
40 cycles of 20 sec 90°C, 20 sec 67°C, 20 sec 72°C; a 
final extension at 72°C 10 min. The heteroduplex cycle 
performed at 95°C 5 min and 40°C 1 min, then, melting 
at 70°C to 90°C with 25 acquisitions/°C and a 1 minute 
cooling to 40°C with a ramp rate of 2.2°C/second.
The LightCycler software plotted the melting peak of 
the fluorescent signal corresponding to the temperature 
Figure 1. HRMA Melting Profiles Obtained from 
Tissues Carrying Mutant KRAS. The figure shows the 
results of Gene Scanning analyses. A) Normalized and B) 
difference graph, containing wild-type samples (green) and 
mutated samples (blue and red)
Figure 2. Pyrosequencing Electropherogram of Wild 
Type (Normal) and Mutant KRAS. (top) Wild type-
(12Gly-GGT, 13Gly-GGC), (middle and bottom) Mutant-KRAS 
(12Asp-GAT, 12Cys-TGT)
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(-dF/dT). The comparison of each patient’s peak plot 
with WT (i.e. DNA isolated from human foreskin 
keratinocytes) and mutant (i.e. DNA isolated from cell 
lines HCT116 or Calu-1) reference DNA KRAS and or 
BRAF mutations identified. 
Pyrosequencing
Extracted DNA samples were amplified for codons 12 
and 13 of KRAS gene using primers from the PyroMark 
KRAS v.2.0 Q96 kit using Veriti 96 well Applied 
BioSystem thermal cycler. PCR reactions for KRAS 
codons 12 and 13 were performed under the following 
condition: the mixture was heated at 95°C 5 min, 45 cycles 
of 95°C 15 s, 57°C 30 s, 72°C 15 s. then, held at 72°C 5 
min. PCR components final concentrations were: 1x PCR 
buffer, 2 mM MgCl2, 0.125 mM dNTPs, 0.2 μM Forward 
primer and 0.2 μM Reverse biotinylated primer, 1U of 
AmpliTaq polymerase (Perkin Elmer, Waltham, USA) 
and 2 ng/μl DNA template. 
BRAF was accomplished in those samples considered 
positive by HRM (like KRAS), in order to confirmation 
of HRM analysis results. After HRM analysis profile, 
Pyrosequencing was carried out using the Qiagen 
PyroMark BRAF kit according to the manufacturer 
protocol. Sequencing primers for BRAF codon 600 were 
obtained from the PyroMarkBraf v.2.0 kit. Sequence 
analysis was conducted using the PyroMark Q96 software.
Running of 12 μl PCR product on 1.5% agarose 
gel (Sigma-Aldrich, St. Louis, USA) used to confirm 
successful amplification. PyroMark Q96 analysis Software 
used to analysis of sequenced PCR products by EpigenDX 
Company (Worcester, USA). Purification of PCR products 
performed by illustra GFX PCR DNA and Gel Band 
Purification Kit (GE Healthcare, Little Chalfont, UK), 
according to manufacturer instructions. 
Sequencing PCR products were run by 1 μL of 
purified PCR amplification products on an PyroMark ID 
Pyrosequencing machine (QIAGEN, Germany) according 
to kit protocol, and the respective electropherograms 
were analyzed with PyroMark Q96 analysis Software 
(QIAGEN, Germany) (Figure2). All electropherograms 
were read manually.
Dxs Therascreen
TheraScreen DxS KRAS Mutation Kits KR-21 and 
KR-22 (QiaGen, Hilden, Germany) that were designed 
to detect six mutations in codon 12 (Gly > Ala, Asp, Arg, 
Cys, Ser, and Val) and one in codon 13 (Gly > Asp) of the 
KRAS oncogene. Internal reaction control and a synthetic 
control template were into commercial test kit. Calculation 
of the KRAS mutation degree were the difference 
between the control reaction and the allele-specific 
reaction. Two characteristics of its primers: 3´ ends were 
sequence-specific to detect mutations (comprise the 
PCR-Amplification Refractory Mutation System, PCR-
ARMSW), and Real-time PCR-Scorpion W primer tags, 
that into double-stranded DNA were fluoresce emission.
LightCyclerW480 II (Roche Applied Science, 
Penzberg, Germany) used for PCR reactions corresponding 
to manufacturer protocol (TheraScreen K-RAS Mutation 
Table 1. Demographical and Pathological Characteristics of CRC Patients
Clinical and pathological characteristics N %
Sex Male 573 57.3
 Female 427 42.7
Age (y) ≤50 325 32.5
 >50 675 67.5
Tumor type Non Mucinous adenocarcinoma 898 89.8
 Mucinous adenocarcinoma 86 8.6
 Signet ring cell adenocarcinoma 16 1.6
Tumor differentiation Well Differentiated 439 43.9
 Moderate Differentiated 384 38.4
 Poor differentiated 164 16.4
 Undifferentiated 13 1.3
pT (Depth of invasion) p Tis 14 1.4
 p T1 14 1.4
 p T2 53 5.3
 p T3 812 81.2
 p T4 107 10.7
Lymph nodes involvement Involved 667 66.7
 Uninvolved 333 33.3
 Mutant 0 0
Pathological Grade Low grade 823 82.3
 High grade 177 17.7
Figure 3. Frequency Distribution of the Different 
Mutation types Found in KRAS
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Kit version DU001PE), by the using of 25 μl total reaction 
volume. The termocycler heating program were: 95°C for 
4 min for initial denaturation, 45 cycles of 95°C 30 sec 
and 60°C 1 min. LightCycler Analysis Software 1.5.0 SP3 
program (Roche Applied Science, Penzberg, Germany) 
used to data analysis.
Statistical analysis
SPSS version 20 software (SPSS Inc., Chicago, IL, 
USA) was used for statistical analyses and the basic 
descriptive and frequency features were used. After the 
calculation of arithmetic and standard mean, double-
sided chi square/fisher-exact tests and t tests were used to 
compare genotype frequency and incidence between the 
various groups. P values less than 0.05 were considered 
to be statistically significant.
Results 
Patient characteristics
A total of 1000 Iranian mCRC patients tested for 
KRAS mutations and 242 subsets (mCRC tissue at 
stage IV) of them analyzed for BRAF mutations using 
HRM, Pyrosequencing and TheraScreen DxS methods, 
respectively. Table 2 characterizes the results by more 
details. 
Frequency of KRAS mutations
We found a mutation of KRAS (codon 12 or 13) in 
33.6% cases (n=336). Of KRAS mutation positive cases 
85.1% were codon 12 mutant and 14.9% were codon 13 
mutant (Table 1). The most common mutation at KRAS 
codon 12 was Gly12Asp, as shown in Figure 3. Other 
mutations founded in codon 12 were Gly12Val, Gly12Ser, 
Gly12Ala, Gly12Cys and Gly12Arg. Also the most 
frequent mutation at codon 13 was Gly12Asp. All detected 
mutations of KRAS in our study have been previously 
described as oncogenic (table3). None of the KRAS 
mutation positive cases had BRAF mutation, respectively.
Frequency of BRAF mutations
We analyzed the mutational status of BRAF gene, 
using HRM and Pyrosequencing methods. Among 242 
patients of our mCRC specimens, BRAF mutations were 
not detected. According to our results the BRAF mutation 
occurs at very low frequency in mCRC.
Associations of Clinicopathological feature with KRAS 
mutations
We analyzed whether KRAS genotypes correlated with 
any distinguishing clinicopathological and morphological 
features, including sex, age of patients, histological 
findings, depth of invasion (pT) and Lymph nodes 
involvement. Our results, as shown in table 2, indicate 
that KRAS mutations occurred at a statistically higher 
frequency in older patients (>50) than in younger patients 
(≤50) (P=0.0001). Further statistical tests revealed that 
KRAS mutations have a tendency to occur in Non-
mucinous adenocarcinoma than other tumor types 
(P=0.0001). In addition, there was a significant association 
of KRAS genotype with depth of invasion, so that KRAS 
mutations occur at a high rate in pT3 than pTis, pT1, pT2 
and pT4 (P=0.0001). It is also worth mentioning that 
KRAS mutation tended to occur at a more frequency in 
male cases than in female cases, according to results of 
Table 2. Frequency of KRAS Mutations According to Clinical and Pathological Features
Clinical and pathological characteristics KRAS wild type KRAS mutant, N (%)
 N (%) Total Codon 12 Codon 13
Sex Male 402 (60.5%) 171 (50.9%) 143   (83.6%) 28 (16.4%)
 Female 262 (39.4%) 165 (49.1%) 143   (86.7%) 22 (13.3%)
Age (y) ≤50 235 (35.4%) 90 (26.8%) 74   (82.3%) 16 (17.7%)
 >50 429 (64.6%) 246 (73.2%) 212   (86.2%) 34 (13.8%)
Tumor type Non-Mucinous adenocarcinoma 602 (90.7%) 298 (88.7%) 250   (83.9%) 48 (16.1%)
 Mucinous adenocarcinoma 46   (6.9%) 38 (11.3%) 34   (89.5%) 4 (10.5%)
 Signet ring cell adenocarcinoma 16   (2.4%) 0   (0.0%) 0     (0.0%) 0   (0.0%)
Tumor Well Differentiated 265 (39.9%) 173 (51.5%) 77   (44.5%) 96 (55.5%)
differentiation Moderate Differentiated 279 (42.0%) 108 (32.1%) 86   (79.6%) 22 (20.4%)
 Poor differentiated 109 (16.4%) 54 (16.1%) 39   (72.2%) 15 (27.8%)
 Undifferentiated 11   (1.7%) 1  (0.3%) 1 (100.0%) 0   (0.0%)
pT (Depth of p Tis 0   (0.0%) 14  (4.2%) 14 (100.0%) 0   (0.0%)
invasion) p T1 14   (2.1%) 0  (0.0%) 0     (0.0%) 0   (0.0%)
 p T2 33   (5.0%) 20  (5.9%) 13   (65.0%) 7 (35.0%)
 p T3 547 (82.4%) 265 (78.9%) 201   (75.8%) 64 (24.2%)
 p T4 70 (10.5%) 37 (11.0%) 33   (89.2%) 4 (10.8%)
Lymph nodes Involved 399 (60.1%) 268 (79.7%) 239   (89.2%) 29 (10.8%)
involvement Uninvolved 265 (39.9%) 68 (20.3%) 58   (85.3%) 10 (14.7%)
Total mCRC 1000 patients  664 (66.4%) 336 (33.6%) 286   (85.1%) 50 (14.9%)
Table 3. Mutations Found in Exon 2 of the KRAS Gene 
(in Codons 12/13)
Gene Codon Analyte Detected mutations
KRAS 12 G12A Gly12Ala c.35G>C GGT>GCT
  G12C Gly12Cys c.34G>T GGT>TGT
  G12D Gly12Asp c.35G>A GGT>GAT
  G12F Gly12Phe c.34_35GG>TT GGT>TTT
  G12R Gly12Arg c.34G>C GGT>CGT
  G12S Gly12Ser c.34G>A GGT>AGT
  G12V Gly12Val c.35G>T GGT>GTT
 13 G13D Gly13Asp c.38G>A GGT>GAC
Asian Pacific Journal of Cancer Prevention, Vol 17, 2016 607
DOI:http://dx.doi.org/10.7314/APJCP.2016.17.2.603
Mutation Analysis of KRAS and BRAF Genes in Metastatic Colorectal Cancer: a First Large Scale Study from Iran.
current study. But this was not a significant difference 
(P=0.7).  
Discussion
Dramatic increasing in colorectal cancer (CRC) 
occurrence over the last thirty years in Iranian population 
made it a main public health problem (Dolatkhah et al., 
2015). Actually, CRC is the fourth most common cancer 
of Iranian society (Mahdavinia et al., 2005) with probable 
number of 3641 new cases annually, from which 2262 
died each year, accounting for almost 6.3% of all cancer 
deaths (Malekzadeh et al., 2009). The discovering of 
mutation patterns in oncogenes and tumor suppressor 
genes (TSGs) potentially can provide a reliable instrument 
on patient management and treatment strategies in CRC. 
The aim of our study was to examine the mutations rate 
of KRAS and BRAF genes in 1000 and 242 Iranian 
population of mCRC patients, respectively, in addition 
to evaluation of association value between genotypes 
of interested genes and clinicopathological features. To 
our knowledge, the current study is the first report on the 
frequency of KRAS and BRAF mutations from a largest 
sample size of metastatic colorectal cancers in Iranian 
population. We here show that BRAF mutations were not 
detected in any of the mCRC tissues analyzed, despite the 
high frequency of KRAS mutations in these lesions. Our 
analysis demonstrated that KRAS mutation was occurred 
in around 33.6% of CRC cases, which included 85.1% of 
cases with mutations at codon 12 and 14.9% of cases with 
mutations at codon 13. Since, it appears that Mutations in 
KRAS codons 12 and 13 are the almost frequently reported 
mutations in CRC patients (Vaughn et al., 2011). These 
results confirm previous reports regarding high rate and 
important role of KRAS mutations in CRC (Spindler et 
al., 2009). Furthermore, the rate of KRAS mutations in 
Iranian population is almost similar to reported rate of 
36% from European countries (Ciardiello et al., 2011). 
This rate in Japan and China is almost 38% (Kadowaki 
et al., 2015, Ye et al., 2015). Although, these results differ 
from some published reported data on frequencies rate 
of KRAS mutations in CRC patients from Middle east 
populations (24%), interestingly (Ciardiello et al., 2011, 
Negru et al., 2014). There are several possible explanations 
like ecological and lifestyle differences between the 
populations or diversity of genetic backgrounds (Negru et 
al., 2014). Also these difference results can be explained 
by variable samples size in considered research. 
In 2008, Simi L and et al. published a paper in which 
they determine rate of approximately 9.5% for mutant 
BRAF in CRCs patients from Italian population (Simi et 
al., 2008). Saridaki Z and coworkers (Saridaki et al., 2011) 
analyzed the data from 112 CRC patients in the Greece 
and concluded the rate of BRAF mutations is 7.2% in the 
Spanish population, studies reported the BRAF mutational 
rate ranges from 6.25% to 13% in CRC patients (Borras 
et al., 2011; Herreros-Villanueva et al., 2011). In Chinese 
(Li et al., 2011), Korean (Kwon et al., 2011) and Thai 
(Hsieh et al., 2012) populations, frequency of mutant 
BRAF in CRCs is 7%, 3.3% and 1.1%, respectively. 
The overall BRAF mutational frequency ranges from 
3.3% to 13% in the different ethnic groups (Hsieh et al., 
2012), But no such rate could be observed in our study 
and we determine all of Iranian mCRC grade IV patients 
contain wild type BRAF gene. This finding of the current 
study are consistent with those of Naghibalhossaini and 
zamani who found no V600E mutation of BRAF gene in 
Iranian population (Naghibalhossaini et al., 2011). It is 
challenging to explain this result, but it might be related 
to geographical variation and different ethnic groups 
(Yokota et al., 2011). Although the sample size in our study 
is reliable, however, it is suggested that further research 
be undertaken. In accordance to reported results in the 
previous literature (Rajagopalan et al., 2002; Ahlquist 
et al., 2008; Amado et al., 2008), KRAS and BRAF 
mutations are mutually exclusive in CRCs. Similarly, our 
results support this hypothesis and shown that none of the 
336 CRCs with KRAS mutations were not coexistent with 
the mutation in BRAF. 
In  o rder  to  a s soc ia t ion  inves t iga t ion  o f 
clinicopathological characteristics with KRAS genotypes, 
we also collected and analyzed the information on patient’s 
sex and age, tumor type, tumor differentiation, lymph nodes 
involvement and depth of invasion. There are a statistically 
significant association between KRAS mutations and 
older patients (more than 50 years) (P=0.0001). These 
observations suggested that KRAS gene is more disposed 
to the mutation with increasing of age. We also found 
that KRAS mutations occurred at a statistically higher 
frequency in non-mucinous adenocarcinoma (P=0.0001), 
and pT3 (P=0.0001). These data proposed that KRAS 
mutations might related to crucial event favoring the 
tumor type of non-mucinous adenocarcinoma and pT3. 
However, the molecular mechanisms of this tendency 
are unclear and more research on this topic needs to be 
under taken. No statistically significant association in 
other selected clinicopathological features were found 
according to KRAS genotypes. In conclusion, the current 
study indicated that 33.6% of 1000 colorectal cancer 
sample in Iranian population showed KRAS mutations. 
Also mutational status of KRAS was associated with 
high age of patients, tumor type of adenocarcinoma non-
mucinous and tumor size of pT3, this is an important issue 
for future research.
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